Skin reactions and discomfort associated with insulin infusion pumps limit user adherence. A recent histopathological study by Kalus et al. (DERMIS study) reported increased eosinophilic infiltration and imputed an inflammatory response to an allergen delivered at the catheter tip. This finding might explain the pruritus reported by pump users. As eosinophils migrate to inflammatory foci, primarily due to IL-5 and CCL11, we aimed to evaluate insulin phenolic preservative (IPP) as a potential allergen in vitro and assess tissue eosinophilic infiltration in vivo.
Methods:
Histopathological evaluations for eosinophil recruitment were performed over 1 week following IPP infusions in swine tissue. Additional histopathological investigations of eosinophilic infiltration were conducted using three commercial glucose sensors implanted in swine for up to 3 weeks.
Results:
Eosinophilic infiltration in the dermis and subcutaneous tissue was observed following saline and IPP infusion and at glucose sensor implantation at all time points examined. In vitro studies revealed IPP eosinophil cytotoxicity. However, neither CCL11 nor IL-5 was detected in any of the tested tissue cells after IPP treatment.
Conclusion:
These findings suggest that IPP is not the only triggering allergen, as IPP did not induce eosinophils in vitro, while glucose sensors also indicated increased eosinophilic infiltration. Therefore, factors other than IPP trigger eosinophil recruitment to insulin infusion pump sets.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association Professional Practice C. 13. Older adults: Standards of care in diabetes-2024. Diabetes Care, 2024; 47,(Suppl 1):S244–S257.
2.
Cardona-HernandezR, SchwandtA, AlkandariH, et al.; SWEET Study Group. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the International Pediatric Registry SWEET. Diabetes Care, 2021; 44(5):1176–1184.
3.
KalusA, ShinoharaMM, WangR, et al.Evaluation of insulin pump infusion sites in type 1 diabetes: The DERMIS study. Diabetes Care, 2023; 46(9):1626–1632.
4.
GleichGJ, AdolphsonCR. The eosinophilic leukocyte: Structure and function. Adv Immunol, 1986; 39:177–253.
5.
HoganSP, RosenbergHF, MoqbelR, et al.Eosinophils: Biological properties and role in health and disease. Clin Exp Allergy, 2008; 38(5):709–750.
6.
RaoSP, GeXN, SriramaraoP. Regulation of eosinophil recruitment and activation by galectins in allergic asthma. Front Med (Lausanne), 2017; 4:68.
7.
BlanchardC, RothenbergME. Biology of the eosinophil. Adv Immunol, 2009; 101:81–121.
8.
GangwarRS, FriedmanS, SeafM, et al.Mast cells and eosinophils in allergy: Close friends or just neighbors. Eur J Pharmacol, 2016; 778:77–83.
9.
ParkYM, BochnerBS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res, 2010; 2(2):87–101.
10.
RosenbergHF, DyerKD, FosterPS. Eosinophils: Changing perspectives in health and disease. Nat Rev Immunol, 2013; 13(1):9–22.
11.
RothenbergME, HoganSP. The eosinophil. Annu Rev Immunol, 2006; 24:147–174.
12.
YiS, ZhaiJ, NiuR, et al.Eosinophil recruitment is dynamically regulated by interplay among lung dendritic cell subsets after allergen challenge. Nat Commun, 2018; 9(1):3879.
13.
Minai-FlemingerY, Levi-SchafferF. Mast cells and eosinophils: The two key effector cells in allergic inflammation. Inflamm Res, 2009; 58(10):631–638.
14.
NagataM, NakagomeK, SomaT. Mechanisms of eosinophilic inflammation. Asia Pac Allergy, 2020; 10(2):e14.
15.
KimHJ, KimCH, LeeDH, et al.Expression of eotaxin in 3T3-L1 adipocytes and the effects of weight loss in high-fat diet induced obese mice. Nutr Res Pract, 2011; 5(1):11–19.
16.
LeeEH, ItanM, JangJ, et al.Eosinophils support adipocyte maturation and promote glucose tolerance in obesity. Sci Rep, 2018; 8(1):9894.
17.
ChenY, DuanY, KangY, et al.Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem, 2012; 287(52):43340–43350.
18.
KesserwanS, MulkaA, SharafiehR, et al.Advancing continuous subcutaneous insulin infusion in vivo: New insights into tissue challenges. J Biomed Mater Res A, 2021; 109(7):1065–1079.
19.
KesserwanS, SadagurskiM, MaoL, et al.Mast cell deficiency in mice attenuates insulin phenolic preservative-induced inflammation. Biomedicines, 2023; 11(8).
20.
WeberC, KammererD, StreitB, et al.Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signaling and MCP-1 release. Toxicol Rep, 2015; 2:194–202.
21.
KesserwanS, LewisBE, MaoL, et al.Inflammation at site of insulin infusion diminishes glycemic control. J Pharm Sci, 2022; 111(7):1952–1961.
22.
KesserwanS, MaoL, SharafiehR, et al.A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation. Drug Deliv Transl Res, 2022; 12(7):1711–1718.
23.
LewisBE, MulkaA, MaoL, et al.Insulin derived fibrils induce cytotoxicity in vitro and trigger inflammation in murine models. J Diabetes Sci Technol, 2023; 17(1):163–171.
24.
van FaassenI, Verweij-van VughtAM, Lomecky-JanousekMZ, et al.Preservatives in insulin preparations impair leukocyte function. In vitro study. Diabetes Care, 1990; 13(1):71–74.
25.
FischkoffSA, PollakA, GleichGJ, et al.Eosinophilic differentiation of the human promyelocytic leukemia cell line, HL-60. J Exp Med, 1984; 160(1):179–196.
26.
IshiharaK, HongJ, ZeeO, et al.Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils. Br J Pharmacol, 2004; 142(6):1020–1030.
27.
WalshGM. Eosinophils: Methods and Protocols. . WalkerJM., editor: Springer New York, New York, NY; 2014.
28.
MulkaA, LewisBE, MaoL, et al.Phenolic preservative removal from commercial insulin formulations reduces tissue inflammation while maintaining euglycemia. ACS Pharmacol Transl Sci, 2021; 4(3):1161–1174.
29.
SwinneyMR, CoxAL, HawkinsED, et al.Insulin, not the preservative m-cresol, instigates loss of infusion site patency over extended durations of CSII in diabetic swine. J Pharm Sci, 2021; 110(3):1418–1426.
TakatsuK. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci, 2011; 87(8):463–485.
32.
OwczarekW, PaplińskaM, TargowskiT, et al.Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis. Cytokine, 2010; 50(2):181–185.
33.
LeeJJ, RosenbergHF. Chapter 6 – Eosinophil Trafficking. Eosinophils in Health and Disease: Academic Press; 2013. p. 121–166.
34.
TeixeiraAL, GamaCS, RochaNP, et al.Revisiting the role of Eotaxin-1/CCL11 in psychiatric disorders. Front Psychiatry, 2018; 9:241.
35.
GaldieroMR, VarricchiG, SeafM, et al.Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer. Front Med (Lausanne), 2017; 4:103.
36.
RobidaPA, PuzzovioPG, PahimaH, et al.Human eosinophils and mast cells: Birds of a feather flock together. Immunol Rev, 2018; 282(1):151–167.
37.
KirshenbaumAS, YinY, SundstromJB, et al.Description and characterization of a novel human mast cell line for scientific study. Int J Mol Sci, 2019; 20(22).
38.
NagataY, SuzukiR. FcepsilonRI: A master regulator of mast cell functions. Cells, 2022; 11(4).
39.
AdebayoSA, SteelHC, ShaiLJ, et al.Investigation of the mechanism of anti-inflammatory action and cytotoxicity of a semipurified fraction and isolated compounds from the leaf of Peltophorum africanum (Fabaceae). J Evid Based Complementary Altern Med, 2017; 22(4):840–845.
40.
CodenME, BerdnikovsS. Eosinophils in wound healing and epithelial remodeling: Is coagulation a missing link? J Leukoc Biol, 2020; 108(1):93–103.
41.
DavoineF, LacyP. Eosinophil cytokines, chemokines, and growth factors: Emerging roles in immunity. Front Immunol, 2014; 5:570.
42.
KayAB, Flood-PageP, Menzies-GowA, et al.Eosinophils in repair and remodelling. Clin Exp All Rev, 2004; 4(s2):229–236.
43.
MeyerholzDK, BurroughER, KirchhofN, et al.Swine models in translational research and medicine. Vet Pathol, 2024; 61(4):512–523.
44.
DidyukO, EconomN, GuardiaA, et al.Continuous glucose monitoring devices: Past, present, and future focus on the history and evolution of technological innovation. J Diabetes Sci Technol, 2021; 15(3):676–683.
